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Several interleukins are involved in the regulation ofB cell maturation (1, 2).
These interleukins are divided into three categories: (a) a factor mainly involved
in the activation of resting B cells (B cell stimulatory factor I [BSF-I/IL-4]),' (b)
a factor for the growth and maturation ofactivated B cells (B cell growth factor
[BCGF-II/IL-5]), and (c) a factor for the terminal differentiation of B cells into
antibody-secreting cells (BSF-2/IL-6) . The cDNAs for these three interleukins
have been cloned (3-6), and the recombinant molecules and specific antibodies
against these molecules have become available, thus accelerating the studies on
their physiological role in the B cell responses.
BSF-2 was originally described as a B cell differentiation factor that acts on
activated B cells or B lymphoblastoid cell lines and induces Ig production (7, 8).
The molecular cloning ofthecDNAfor BSF-2 has revealedthatBSF-2 is identical
with the molecules called IFN-a2, 26-kD protein, and hybridoma plasmacytoma
growth factor (HPGF), whose cDNAs have been cloned or whose partial amino
acid sequence has been determined, essentially at the same time (9-11). The
results suggest that the function of BSF-2 may not be restricted to B cells.
Actually, it was shown that BSF-2 could stimulate liver cells to induce acute-
phase proteins as hepatocyte-stimulating factor (HSF) (12, 13). However, BSF-2
did not have any antiviral activity (14, 15), although it has been called IFN-(32
(10). Considering thevariety ofbiological activitiesofBSF-2, it hasbeen proposed
that BSF-2 be called interleukin 6 (IL-6) (14, 16).
This study reports on the role of recombinant BSF-2 (rBSF-2) in the B cell
response. Theresults show that rBSF-2 acts on normal activated B cells to induce
Ig production in the absence of growth induction. However, rBSF-2 shows a
potent growth activity on murine hybridoma cells. The observations made with
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' Abbreviations used in this paper:
￿
BCGF, B cell growth factor; BSF, B cell stimulatory factor;
HPGF, hybridoma plasmacytoma growth factor; HSF, hepatocyte-stimulating factor; MNC, mono-
nuclear cells; RA, rheumatoid arthritis; SAC, Staphylococcus aureus Cowan I.
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anti-BSF-2 antibody demonstrate that BSF-2 is one of the essential molecules in
the PWM-induced Ig production in B cells.
Materials and Methods
Reagents.
￿
PWM was purchased from Sigma Chemical Co. (St. Louis, MO). Phytohe-
magglutinin (PHA) and Staphylococcus aureus Cowan I (SAC) were obtained from Phar-
macia Fine Chemicals Co. (Uppsala, Sweden). Anti-human k chain-specific antibody and
anti-mouse A chain-specific antibody were purchased from Cappel Laboratories (Coch-
ranville, PA). rIL-1,B was kindly provided from Otsuka Pharmaceutical Co. Ltd. (Toku-
shima, Japan) and rIL-2 from Ajinomoto Co. Inc. (Tokyo,Japan).
Preparation of rBSF-2.
￿
rBSF-2 was prepared as described previously (15). Briefly, the
plasmid pTBCDF-12 whose expression was under the control of Escherichia coli trp
promoter was constructed using pT9-11 (17). rBSF-2 was produced as a fusion protein
with a part of IL-2 which was further digested with kallikrein (EC 3.4.21.34) followed
with aminopeptidase-P (EC 3.4.11.9) treatment to obtain the mature rBSF-2 protein. The
rBSF-2 waspurified by reverse-phase HPLC. Thepurity ofrBSF-2 was>95%,as estimated
by SDS-PAGE.
Preparation ofPolyclonal Anti-BSF-2 Antibodies.
￿
Rabbits were immunized with 50 Fcg
of rBSF-2 in CFA at 2-wk intervals for 2 mo as described previously (15). The IgG
fractions of the antiserum and preimmune serum were prepared by ion-exchange chro-
matography. F(ab')2 fragments of the IgG fractions were prepared by a standard pepsin
digestion method (18). The anti-BSF-2 antibody bound rBSF-2 and partially purified
natural BSF-2 derived from bladder cell carcinoma T24, but did not bind rIL-1,8, rIL-2,
IFN-,B, rIFN-y, or recombinant granulocyte colony stimulating factor (rG-CSF). Further-
more, anti-BSF-2 antibody inhibited the rBSF-2 or natural BSF-2-induced Ig production
in the EBV-transformed B cell line, SKW6-CL4, as well as [sH]TdR uptake in the BSF-2-
dependent murine hybridoma, MH60.BSF2 cells. However, it did not inhibit theantiviral
activity of IFN-,B as described elsewhere (15, and Hirano, T., M. Matsuda, M. Turner, et
A., manuscript submitted for publication).
Cell Preparation. Heparinized peripheral blood was drawn from healthy donors.
Tonsils were obtained at tonsillectomy from patients with chronic tonsillitis. The mono-
nuclear cells (MNC) of peripheral blood or tonsillar cells were separated by the Ficoll-
Paque gradient method (19). E-rosette-positive and -negative cells were separated from
PBMC or tonsillar MNC by twice rosetting with 2-aminoethylisothiouronium bromide
(AET)-treated sheep erythrocytes (E). E-rosette-positive cells were used as T cells. E-
rosette-negative cells were further treated with anti-Leu-1 mAb (Becton Dickinson and
Co., Sunnyvale, CA) and rabbit complement. Recovered cells, usually containing >90%
sIg+ cells, <0 .1 % E' cells and monocytes, were used as purified B cells. In some
experiments, in vitro-activated B cells that had been incubated with either SAC or PWM
were separated into high-density B (small B) cells and low-density B cells (B cell blasts) by
using a discontinuous Percoll gradient centrifugation . ^"2 X 10' purified B cells were
layered on top of the gradients, and the tubes were centrifuged at 1280 X g for 15 min
at 4 'C. B cells with low density and high density were recovered in fractions between
40/50% and 60/70%, respectively.
Determination ofIL-1, IL-2, BSF-1/IL-4, BCGF-II/IL-5, BCGF, andHPGF Activities.
￿
All
cultures were done using 96-well flat-bottomed microplates (2596; Costar, Cambridge,
MA) in 0.2 ml of RPMI 1640 containing 10% FCS (Lot No. 5319; Gibco Laboratories,
Grand Island, NY), 100 U/ml penicillin, 100 rig/ml streptomycin, 2 MM L-glutamine, and
5 X 10-5 M 2-ME. To measure IL-1 activity, thymocytes from 7-wk-old BALB/c mice (2
X 106/well) were cultured for 3 d with 1 ug/ml PHA in the presence of test samples. For
measuringIL-2 activity, 5 X lO' cells of the IL-2-dependent murine T cell line,MTH41 .16
(19), were cultured with test samples for 24 h. To examine BSF-1/IL-4 activity, splenic B
cells from 6-wk-old BALB/c mice (5 X 104/well) or human tonsillar B cells (2 X 105/well)
were cultured with test samples for 3 d in the presence of 10 ug/ml of anti-,u antibody
(20, 21). For measuring BCGF-II/IL-5 activity, murine BCL-I cells (105/well), a kind gift334 RECOMBINANT B CELL STIMULATORY FACTOR 2 AND ITS ANTIBODY
of Dr. E. S. Vitetta (University of Texas, Health Science Center, Dallas, TX), were
cultured with test samples for 3 d as described previously (22). BCGF activity was measured
by using SAC-activated B blast cellsas described before (23). For measurements of HPGF
activity, the BSF-2-dependent murine hybridoma clone, MH60.BSF2, was cultured at a
cell concentration of 5 X 104/ml with test samples for 48 h. MH60 .BSF2 hybridoma was
established as a clone producing mAb against human BSF-2 (Matsuda, M., et al., manu-
script in preparation). Its growth was shown to be absolutely dependent on BSF-2, as
described elsewhere (Hirano, T ., M. Matsuda, M. Turner, et al., manuscript submitted
for publication). All cultures were pulsed with 1 pCi of [9H]thymidine ([sH]TdR)(15 .1
Ci/mmol; New England Nuclear, Boston MA) during the last 6 or 16 h, as indicated, and
cells were harvested on glass filter paper by an automated cell harvester (Labo Mash
Science Co., Tokyo, Japan). The radioactivity was measured with a Beckman scintillation
counter (Beckman Instruments, Inc., Fullerton, CA). All assays were performed in
triplicate cultures.
Measurement ofBSF-2 Activity.
￿
EBV-transformed B cell lines, SKW6-CL-4 and SGB29,
were cultured at 5 X 104/ml with test samples in the microplates for 4 d and IgM and
IgG were measured by ELISA as described previously (7).
PWM-induced Ig Production.
￿
MNC obtained from peripheral blood or tonsils or PWM-
stimulated B blast cells were cultured at a cell density of 2 X 105/well in the presence or
absence of PWM together with various concentrations of test samples in the microplates
for various periods as indicated. In some experiments, IgG fractions or F(ab')2 fractions
of antibodies were added to the cultures. Culture medium was replaced with fresh medium
supplemented with test samples or antibodies every 4 d. The concentrations of Ig in the
culture supernatant were determined by ELISA.
Results
rBSF-2 Induces Ig Production in a B Cell Line and in Activated Normal B
Cells. rBSF-2 induced IgM production in an EBV-transformed B cell line,
SKW6-CL-4 (Fig. 1 A), and IgG production in another cell line, SGB29 (Fig. I B)
in a dose-dependent manner, but an equivalent amount of mock preparation did
not cause Ig production. The maximum Ig production in those cells was observed
at a concentration of 2-20 ng/ml of rBSF-2 and 50% of the maximum response
was obtained at a concentration of around 0.2 ng/ml, the specific activity of
rBSF-2 being estimated as 5 X 106 U/mg. To examine the effect of rBSF-2 on
Ig production of normal B cells, tonsillar MNC were cultured in the presence of
varying concentrations of PWM together with rBSF-2 (1 ng/ml or 10 ng/ml) for
8 d and the amounts of Ig in the culture supernatants were determined.
Representative data of three experiments with essentially similar results are
shown in Fig. 2. The addition of rBSF-2 to the culture augmented IgM, IgG,
and IgA productions 3-10-fold. Equivalent amounts of mock rBSF-2 preparation
did not show any enhancing effect (data not shown). When rBSF-2 was added
into the culture of peripheral blood MNC with PWM, a similar enhancement of
PWM-induced Ig production was observed (Fig. 3). As shown in Fig. 3, kinetic
studies with PWM-stimulated peripheral MNC in the presence or absence of
rBSF-2 showed that rBSF-2 did not change the kinetics of the response but
simply augmented the peak response; suggesting that rBSF-2 may enhance the
process normally occurring in the response.
Then it was examined whether rBSF-2 acted directly on B cells. Purified B
cells were stimulated with PWM in the presence of irradiated T cells for 3 d and
B blast cells were obtained . These B blast cells were cultured with various
concentrations of rBSF-2 for an additional 3 d and the concentrations of IgG in10
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FIGURE 1 .
￿
rBSF-2 induces Ig production in EBV-transformed B cell lines, SKW6-CL-4 and
SGB29 . SKW6-CL-4 (A) or SGB29 (B) cells were cultured with various concentrations of
rBSF-2 (0) or mock preparation (Q) . Concentrations of IgM (SKW6-CL-4) or IgG(SGB29) in
the culture supernatants were determined on day 4. Data are shown as means ± SEM of the
triplicate cultures .
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were determined by ELISA . Data are shown as means
SEM of the triplicate cultures.
the culture supernatants were determined . As shown in Fig . 4A, rBSF-2 induced
IgG production in activated B cells in a dose-dependent manner, but had no
effect on unstimulated B cells . The equivalent amount of mock preparation did
not induce Ig production in PWM-stimulated B blasts (data not shown) . Contrary336 RECOMBINANT B CELL STIMULATORY FACTOR 2 AND ITS ANTIBODY
Duration of culture ( days )
FIGURE 3. Enhancing effects of rBSF-2 on
PWM-induced Ig production of PBMC. PBMC
were cultured in thepresence ofPWM without
(p) or with 2 ng/ml (/) or 20 ng/ml (0) of
rBSF-2 for various days as indicated. The con-
centrations of IgG in the culture supernatant
were determined. Results are shown as means
± SEM of the triplicate cultures by ELISA.
to this, rBSF-2 did not induce [sH]TdR uptake in activated B cells, whereas rIL-
2 promoted cell proliferation ofthe same activated B cell population (Fig. 4B).
Effects ofAnti-BSF-2 Antibody on the PWM-induced Ig Production. The role of
BSF-2 in PWM-induced Ig production was further demonstrated using the
antibody specific to BSF-2. Peripheral blood MNC were cultured with PWM
together with various concentrations ofanti-BSF-2 for 8 d. As shown in Fig. 5A,
the PWM-induced IgG production was inhibited up to 80% by the addition of
anti-BSF-2 antibody. The inhibition was also caused by the F(ab')2 fragment of
anti-BSF-2 antibody, indicating that the inhibition was not mediated through the
Fc receptor. However, anti-BSF-2 antibody had no effect on PWM-induced
[3H]TdR uptake, which was measured on days 3 and 7 (Fig. 5B).
To examine whether the inhibition of PWM-induced Ig production by anti-
BSF-2 can be overcome with rBSF-2, peripheral blood MNC were cultured with
PWM and anti-BSF-2 (50 jug/ml) in the presence of different concentrations of
rBSF-2 for 7 d. The levels of IgG in the culture supernatants were determined
by ELISA. As shown in Fig. 6, the inhibitory effect of anti-BSF-2 was reversed
by the addition of rBSF-2 in a dose-dependent manner.
To examine on which stage of PWM-induced Ig production BSF-2 exerts its
effects, anti-BSF-2 antibody was added either at the initiation or on the 4th day
ofthe culture. The amountsofIgG produced were measured on day 8. As shown
in Fig. 7, anti-BSF-2 antibody was effective even when added on day 4 of the
culture.
Effects of rBSF-2 on a Variety of Cells Responsive to Different Kinds of Interleu-
kins.
￿
As shown in Table 1, rBSF-2 did not show any IL-1 or IL-2 activity. ThisMURAGUCHI ET AL.
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FIGURE 4.
￿
Effectsof rBSF-2 on PWM-stimulated B blast cells. PWM-stimulated B blast cells
(O) or unstimulated B cells (p) were cultured with various concentrations of rBSF-2 for 3 d.
The concentrations of IgG in the culture supernatant were determined by ELISA (A). PWM-
stimulated B blast cells were cultured with various concentrations of rBSF-2 (") or OL-2 (O)
for 3 d and ['H]TdR uptake was measured (B). Results are shown as means ± SEM of the
triplicate cultures.
was demonstrated by a costimulatory assay using PHA-stimulated murine thy-
mocytes or examining proliferation-inducing ability in the murine IL-2-depend-
ent T cell line, MTH41.16. rBSF-2 did not induce any increase of [sH]TdR
uptake ofanti-IgM-stimulated human or murine B cells or murine BCGF-II/IL-
5-responsive cell line, BCL-1. In addition, rBSF-2 did not cause any proliferation
in SAC-activated B cells.
BSF-2 Is a Potent Growth Factorfor Hybridoma Cells.
￿
As shown in Fig. 8, rBSF-
2 induced [sH]TdR uptake of murine hybridoma, MH60.BSF2 cells, in a dose-
dependent manner. The maximum response was observed at a concentration of
20 pg/ml of rBSF-2 and the half-maximum response at a concentration of -5
pg/ml of rBSF-2, indicating that the amount of BSF-2 required for the growth
ofMH60.BSF2 is 40 times less than that for Ig induction in SKW6-CL-4 cells.
Discussion
The process through which antigen-stimulated B cells mature into antibody-
forming cells could be dissected into three stages; activation, proliferation, and
differentiation. Several interleukins have been demonstrated to be involved in
each phase ofthe B cell responses (1, 2) and BSF-2 has been classified as a factor
that mainly induces terminal differentiation ofB cells (2, 8). In this report, using
rBSF-2, it was confirmed that BSF-2 in fact induces Ig production in PWM-
activated B cells without any effect on cell proliferation. The most important
result in this study is that anti-BSF-2 antibody almost completely inhibited PWM-338 RECOMBINANT B CELL STIMULATORY FACTOR 2 AND ITS ANTIBODY
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FIGURE 5.
￿
Effect of anti-BSF-2 antibodies on PWM-induced Ig production and cell prolif-
eration of PBMC. PBMC were cultured in the presence of PWM with or without various
concentrations of IgG fraction or F(ab')2 fraction of rabbit IgG(RGG) (O, O) or anti-BSF-2
(aBSF-2) antibody (", "). (A) The concentrations of IgG in the culture supernatants were
determined on day 8. (B) Incorporation of [5H]TdR by the cultured cells was measured on
day 3 and day 7. Results areshown as means ±SEM.
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FIGURE 6.
￿
Reverse effect of rBSF-2 on the anti-
BSF-2-induced inhibition of PWM-stimulated Ig
production. PBMC (105/well) were cultured with
PWM (O) or PWM plus anti-BSF-2 antibody (50
Fig/ml) in the presence of various concentrations
of rBSF-2 (") for 7 d. The concentrations of IgG
in the culture supernatants were determined by
ELISA. Data are shown as means ± SEM.MURAGUCHI ET AL.
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FIGURE 7. Effect of the addi-
tion time of anti-BSF-2 antibody
on its inhibitory effect on PWM-
induced Ig production of PBMC.
PBMC were cultured in the pres-
ence of PWM. Normal rabbit IgG
(NRGG) or anti-BSF-2 antibody
was added to the culture on day
0 or day 4and theconcentrations
of IgG were determined on day
8. Results are shown as means ±
SEM.
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* BALB/c (6 wk) thymocytes (2 X 106/well) were stimulated for 8 dwith rBSF-2 or 10 U/ml of rIL-1 in the presence of PHA-P (I
vg/ml).
IL-2-dependentmurine cell line, MTH41 .16 cells, were stimulated for 24 h with rBSF2 or 10 U/ml ofrIL-2.
BALB/c splenic Bcells (5 X 104/well) or human tonsillar Bcells (106/well) were stimulated for 9 dwith rBSF-2 or 20 kl ofPMA-
stimulated EL4 supernatant (EL4-sup) (for murine B cells) or40,u] of PHA-stimulated human Tcell supernatant (T-sup) (for human
B cells).
1 Murine BCL-1 cells were stimulated for 8 d with rBSF-2 or 20,U1 of EL4-sup.
Human SAC-stimulated Bblasts were stimulated for 9 d with rBSF-2 or 40 Al of T-sup. Data shown as means tSEM of triplicate
cultures.
induced Ig production, indicating that BSF-2 is one ofthe essential factors for
PWM-induced Ig production in B cells. Anti-BSF-2 antibody was effective even
when added on the fourth day ofa total 8-d culture, indicating that BSF-2 acts
on the late phase of the B cell response rather than the early activation phase.
This is in complete agreement with the previous reports demonstrating that BSF-
2 is a late acting factor for the Ig induction in SAC-activated B cells (24, 25). In
accordance with this data, Taga et al. (26) previously reported that BSF-2-
receptor was expressed on the activated B cells but not on resting B cells. As
reported previously with purified BSF-2 (7), rBSF-2 has no effect on the growth
ofanti-IgM, SAC, or PWM-stimulated B cells. Furthermore, anti-BSF-2 antibody,
which suppressed PWM-induced Ig production, did not inhibit PWM-induced
cell proliferation, indicating that BSF-2 is not involved in the PWM-induced
proliferation ofBcells. The results also excluded thepossibilitythat theinhibitory
effect of anti-BSF-2 on Ig production was due to nonspecific cytotoxic effect on
activated B cells.
Assay Target cells Negative
control
Positive
control
[sH]Thymidine incorporation after
adding recombinant BSF-2
0.2 ng/ml 2 ng/ml 20 ng/ml
cpm
IL-1 * Mousethymocytes 7,500 t800 201,000 t6,800 9,200 t600 8,600 t500 9,900 t700
IL-2$ MTH 41 .16 2,900 t400 98,900 t 2,700 2,900 t 100 9,800 t200 8,500 t200
BSF-1/IL-41i Murine anti-)-stimulated 9,200 t200 98,600 t2,000 2,200 t 100 1,800 3200 2,900 t900
Bcells
Human anti-p-stimulated 1,500 t200 72,000 t 1,800 1,600 t200 1,500 t 100 1,900 t200
Bcells
BCGF-II/IL-51 Murine BCL-I cells 200 t 100 9,200 t800 400 t 100 200 t 100 200 t 100
BCGF Human SAC-stimulated 1,100 t200 9,500 t 800 1,200 t 200 1,100 t 100 900 t 100
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FIGURE 8.
￿
rBSF-2 induces cell growth of the
murine hybridoma clone, MH60.BSF2.
MH60.BSF2 cells were cultured with various
concentrations of rBSF-2 (4p) or mock prepa-
ration (O) and [sH]TdR uptake was measured
on day 2. Data are shown as means t SEM of
thetriplicate cultures.
These functional properties of BSF-2 are quite different from those of BSF-
1/IL-4 (3, 4, 27), BCGF II/IL-5 (5) and neuroleukin (28). BSF-1/IL-4 activates
resting B cells (29) and induces proliferation of B cells together with anti-IgM
(4, 20). BSF-1/IL-4 can induce IgGI and IgE production in murine LPS-
stimulated B blast cells (3, 30). However, the activity of BSF-1/IL-4 to induce Ig
production was demonstrated to be exerted on resting B cells (31). BSF-1/IL-4
is thus considered an activation factor. In fact, the receptors for BSF-I/IL-4
were shown to be expressed on resting B cells, in contrast to BSF-2 receptors
which are expressed only on activated B cells (26, 32, 33, 34). BCGF-II/IL-5
promotes proliferation of dextran sulfate-stimulated B cells and B lymphoma
cell line, BCL-1, and induces Ig production in activated B cells (5, 35, 36).
Therefore, BCGF-II/IL-5 is a factor with growth and differentiation activities.
This is in contrast to the function of BSF-2, which induces only Ig production in
B cells without any growth activity. Neuroleukin was demonstrated to be one of
the essential factors for PWM-induced Ig production, but its effect was restricted
in an early phase of B cell response, since antineuroleukin antibody inhibited
PWM-induced Ig production only when it was added at the initiation of culture
(28). Neuroleukin may directly act on B cells but the presence of T cells and
monocytes is essential for neuroleukin-induced Ig secretion in B cells, indicating
that several other factors such as BSF-2 are required for the process of B cell
differentiation . In any case, the studies with antineuroleukin and anti-BSF-2
antibodies indicate that both factors are involved in the early and late stages of
the PWM-induced B cell response, respectively.MURAGUCHI ET AL.
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rBSF-2 enhanced PWM-induced IgM, IgG, and IgA production, suggesting
that BSF-2 has no preferential effect on certain isotypes of Ig in contrast to BSF-
1/IL-4, IFN-,y, and BCGF-II/IL-5 which display preferential effect on certain
classes and/or subclasses of murine Ig; BSF-1/IL-4 for IgGI and IgE, IFN--Y for
IgG2a (30, 37), and BCGF-II/IL-5 for IgA (38). However, BSF-2 might have
preferential effect on a specific isotype of Ig, such as IgG2b. Al-Balaghi et al.
(39) reported that synovial fluid of patients with rheumatoid arthritis (RA)
contained factor(s) that preferentially induced IgG2b in LPS-stimulated murine
B cells. They called the active factor BCDF and demonstrated that BCDF
enhanced PWM-induced Ig production in human peripheral blood MNC without
any effect on cell proliferation. They also showed that BCDF was directly
effective on activated B cells. The functional properties of synovia-derived BCDF
and BSF-2 seem to be similar. In fact, we recently found that synovial fluid
obtained from affected joints of RA patients contains BSF-2 (Hirano, T ., M.
Matsuda, M . Turner, et al., manuscript submitted for publication). These find-
ings suggest that BSF-2 might have preferential effect on the expression of IgG2b
and this possibility remains to be determined.
The data presented in this report indicate that BSF-2 has no growth-inducing
activity in normal activated B cells. However, rBSF-2 was a potent growth factor
for a murine hybridoma cell line, MH60.BSF2, in complete agreement with the
results obtained by Van Damme et al. (11) and Poupart et al. (14) . rBSF-2
induced 50% of the maximum [sH]TdR uptake of MH60 .BSF2 at a concentra-
tion of ^" 5 pg/ml, the specific activity being calculated as 2 X 10' U/mg. The
specific activity of rBSF-2 estimated on the basis of the Ig-inducing activity of
EBV-transformed B lymphoblastoid cell line, SKW6-CL-4, is 5 X 106 U/mg. Van
Snick et al. (40) also showed that hybridoma cells required 200 times lower BSF-
2 than that required for plasmacytoma growth. The reasons why hybridoma cells
are more sensitive to BSF-2 than plasmacytomas or B cell lines is not known.
This could be explained by the assumption that the degree of the saturation of
the receptor molecules with BSF-2 required for its functional expression might
be different among a variety of cells. Alternatively, the presence of two classes
of receptors with different affinity would cause the different sensitivity to BSF-
2. This seems unlikely since the analysis of the BSF-2-receptor on various cells
showed the presence of only a single class of receptor with high affinity (26).
In this study, the essential role of BSF-2 in Ig induction was demonstrated in
PWM-stimulated B cells using rBSF2 and anti-BSF2 antibody. It should be
examined whether the results obtained with mitogen-stimulated B cells could be
applied to the antigen-specific antibody response.
Summary
The role of recombinant B cell stimulatory factor 2 (BSF-2/IL-6) in the
regulation of growth and differentiation of B cells was investigated. rBSF-2 at
200 pg/ml could induce 50% of the maximum Ig production in B lymphoblastoid
cell lines, the specific activity being estimated as 5 X 106 U/mg. rBSF-2 aug-
mented PWM-induced IgM, IgG, and IgA production in mononuclear cells
(MNC); the effect was exerted by directly acting on PWM-induced B blast cells
to induce Ig production. However, rBSF-2 did not induce any growth ofactivated342 RECOMBINANT B CELL STIMULATORY FACTOR 2 AND ITS ANTIBODY
B cells. In contrast, rBSF-2 showed a potent growth activity on a murine
hybridoma clone, MI-160.11M . The concentration required for half-maximal
[3H]TdR uptake was ^-5 pg/ml, which was 40 times less than that required for
Ig induction in a B cell line. Anti-BSF-2 antibody inhibited PWM-induced Ig
production in MNC, but not PWM-induced proliferation. The antibody was
effective even when added on day 4 of an 8-d culture, indicating that BSF-2 is
one of the essential late-acting factors in PWM-induced Ig production .
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